- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02413684
PackHealth: Asthma Engagement Tool
Assessing the Impact of a Patient-Clinician Engagement Tool on Patient Reported Outcomes and Engagement in Asthma
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Patient engagement is a critical part of improving patient care and outcomes. Current patient engagement strategies only focus on the patient-physician interaction and have been shown to be ineffective.
The need for a comprehensive approach to patient engagement is no different among patients with asthma as it is in any other chronic condition. Patients with asthma must make complicated health decisions daily that impact their social and occupational activities, quality of life, and treatment adherence. Obtaining, communicating, processing, and understanding non- biased health information are crucial in making appropriate and informed treatment decisions.
Pack Health LLC and Duke will develop a patient engagement toolkit known as "Packs" to help empower and engage patients. These disease-specific, evidence-based kits are scientifically designed to improve patient involvement in their own care. Each Pack draws on the science of change management and patient activation and contains three categories of materials
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27705
- Duke Asthma Allergy and Airway Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patients with a physician diagnosis of asthma for at least the previous 12 months.
- Asthma that is not well controlled by NAEPP guidelines.
- Ability and willingness to provide informed consent
Exclusion Criteria:
- Significant alcohol consumption of more than three alcoholic drinks per day or active substance abuse.
- Chronic disease (other than asthma) that in the opinion of the investigator would prevent participation in the trial or put the participant at risk by participation e.g. chronic diseases of the lung (other than asthma), heart, liver, kidney, endocrine or nervous system or immunodeficiency that are not well addressed or controlled.
- A diagnosis of cancer with ongoing treatment.
- Any terminal illness or conditions that results in a life expectancy less than one year.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Altro: Asthma Patients
Patient engagement toolkit
|
Pack Health LLC and Duke will develop a patient engagement toolkit known as "Packs" to help empower and engage patients.
These disease-specific, evidence-based kits are scientifically designed to improve patient involvement in their own care
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Rate of Asthma Exacerbations
Lasso di tempo: 12 weeks prior to baseline
|
The average number of asthma events requiring treatment with oral corticosteroids, emergency room visits or hospitalizations that occurred 12 weeks before baseline.
|
12 weeks prior to baseline
|
|
Rate of Asthma Exacerbations
Lasso di tempo: baseline to week 13
|
The average number of asthma events requiring treatment with oral corticosteroids, emergency room visits or hospitalizations from baseline to week 13
|
baseline to week 13
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Asthma Control
Lasso di tempo: baseline, 13 weeks
|
Measured by the Asthma Control Test (ACT), patient self-administered tool for identifying those with poorly controlled asthma.
The ACT assesses the frequency of dyspnea and general asthma symptoms, use of rescue medications, the effect of asthma on daily functioning, and overall self-assessment of asthma control.
5 items with 4-week recall.
The score range is 5-25 with >19 representing good control and <18 representing poor control.
|
baseline, 13 weeks
|
|
Change in Asthma Symptoms
Lasso di tempo: baseline, 13 weeks
|
Measured by asthma symptom utility index (ASUI). The Asthma Symptom utility Index (ASUI) is a brief, interviewer-administered, patient preference-based scale assessing frequency and severity of asthma-related symptoms and treatment side effects. Number of items 11 items with 2 week recall. Scores range from 0 (worst possible symptoms) to 1 (no symptoms) Minimal Clinically Important Difference (MCID) > 0.09 |
baseline, 13 weeks
|
|
Change in Pulmonary Function Tests
Lasso di tempo: baseline, 13 weeks
|
Measured by spirometry.
We measured forced expiratory volume in one second (FEV1) and forced vital capacity both in liters.
FEV1 is a measure of airflow obstruction.
The change in lung function is the change in these measurements compared to baseline.
|
baseline, 13 weeks
|
|
Number of Emergency Department and Hospitalization Visits
Lasso di tempo: Prior Year
|
Number of emergency department and hospitalizations visits will be recorded that occurred within the prior year.
|
Prior Year
|
|
Number of Emergency Department and Hospitalization Visits
Lasso di tempo: 13 weeks
|
Number of emergency department and hospitalization visits will be recorded
|
13 weeks
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Njira Lugogo, MD, Duke University
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- Pro00057939
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Patient engagement toolkit
-
Brigham and Women's HospitalGordon and Betty Moore FoundationCompletatoPazienti dell'Unità di Terapia Intensiva Medica (MICU). | Pazienti dell'Unità di OncologiaStati Uniti
-
The University of QueenslandRestorative Outcomes Australia; Department of Education, Queensland; Queensland... e altri collaboratoriSconosciutoComportamento antisociale | Frequenza scolastica | Dipendenza dal benessereAustralia
-
Dana-Farber Cancer InstituteNational Institute on Aging (NIA)Reclutamento
-
Hasan Kalyoncu UniversityCompletatoAnsia | Gestione del dolore | Infertilità (pazienti IVF)Turchia (Türkiye)
-
University of MichiganCompletatoDonne con mutazione BRCA 1 o BRCA 2 | Membri femminili della famiglia non testatiStati Uniti
-
Ankara City Hospital BilkentCompletato
-
NYU Langone HealthPatient-Centered Outcomes Research InstituteReclutamento
-
Médipôle Lyon-VilleurbanneCompletatoArresto cardiaco | Insufficienza cardiaca acuta (AHF)Francia
-
University of TorontoUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; McMaster... e altri collaboratoriCompletato
-
Optimum Patient CareRespiratory Effectiveness Group; Boehringer Ingelheim Pharmaceutical Company... e altri collaboratoriSconosciutoBroncopneumopatia Cronica Ostruttiva (13645005)Stati Uniti